Ribosomal protein L23a pseudogene 26 (RPL23AP26)

Ribosomal protein L23a pseudogene 26 (RPL23AP26) is a processed pseudogene corresponding to the structural ribosomal protein gene RPL23A, annotated in the human genome but not believed to encode a functional protein[1][6]. Pseudogenes are typically non-coding genomic sequences similar to known genes, resulting from gene duplication or retrotransposition events. RPL23AP26 is one of many ribosomal protein L23a pseudogenes and is not known to have a direct biological function, play a role in disease, or serve as a drug target. Currently, there is no evidence implicating RPL23AP26 in cellular processes or pathology, nor is it used as a biomarker or therapeutic target[1][6]. RPL23AP26 is not a canonical therapeutic target. It is a pseudogene, not an active protein, enzyme, receptor, or other functional molecule in classical pharmacology or molecular biology[1][6]. There is some literature on ribosomal protein L23a pseudogenes in general (e.g., RPL23AP53 and melanoma), but there is no data linking RPL23AP26 specifically to any function, disease, or therapeutic process[2]. Pseudogenes are sometimes noted for potential regulatory roles or as transcripts, but this is case-dependent and not established for RPL23AP26. If your query intended a functional ribosomal protein or a different pseudogene, double-check the spelling or number. If you are seeking a functional ribosomal protein, refer to "Ribosomal protein L23a" (RPL23A), not pseudogene forms[3][5][7].

Other names

RPL23A_14_334RPL23AP26